- 米国企業
- Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plcJAZZ
時価総額
$68億
PER
16.4倍
| 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | |
| Product sales, net | - | - | - | - | - | - | - | - | - | 2,347 | 3,079 | 3,641 | 3,737 |
| Royalties and contract revenues | - | - | - | - | - | - | - | 21 | 26 | 17 | 15 | 18 | 97 |
| Total revenues | 272 | 586 | 872 | 1,173 | 1,325 | 1,488 | 1,619 | 1,891 | 2,162 | 2,364 | 3,094 | 3,659 | 3,834 |
| Cost of product sales (excluding amortization of acquired developed technologies) | - | - | - | 117 | 103 | 105 | 110 | 122 | 128 | 149 | 441 | 541 | 436 |
| Selling, general and administrative | 109 | 224 | 304 | 406 | 449 | 503 | 544 | 684 | 737 | 854 | 1,452 | 1,417 | 1,343 |
| Research and development | - | - | - | - | - | - | - | - | - | 335 | 506 | 590 | 850 |
| Intangible asset amortization | 7 | 73 | 79 | 127 | 98 | 102 | 152 | 201 | 355 | 260 | 526 | 599 | 608 |
| Asset Impairment Charges | - | - | - | 39 | 32 | - | - | 43 | - | 136 | - | 134 | - |
| Acquired in-process research and development | - | - | - | 203 | - | 24 | 85 | - | 110 | 251 | - | 444 | 19 |
| Acquired in-process research and development | - | - | - | 203 | - | 24 | 85 | - | 110 | 251 | - | 444 | 19 |
| Asset Impairment Charges | - | - | - | 39 | 32 | - | - | 43 | - | 136 | - | 134 | - |
| Total operating expenses | - | - | - | - | - | - | - | - | 1,629 | 1,985 | 2,924 | 3,725 | 3,256 |
| Income (loss) from operations | 128 | 198 | 340 | 196 | 508 | 592 | 529 | 615 | 532 | 378 | 170 | -66 | 579 |
| Interest expense, net | - | -17 | -27 | -53 | -57 | -62 | -78 | -77 | -72 | -100 | -279 | -288 | -289 |
| Foreign exchange gain (loss) | - | - | - | - | - | 3 | -10 | -7 | -6 | -3 | -4 | -19 | 9 |
| Income (loss) before income tax expense (benefit) and equity in loss of investees | - | - | - | - | - | 532 | 441 | 529 | 454 | 275 | -113 | -373 | 298 |
| Income tax expense (benefit) | - | -84 | 92 | 94 | 106 | 135 | -48 | 80 | -73 | 34 | 216 | -159 | -120 |
| Equity in loss of investees | - | - | - | - | - | -0 | -1 | -2 | -4 | -3 | -1 | -10 | -3 |
| Net income (loss) | 125 | 289 | 216 | 58 | 330 | 397 | 488 | 447 | 523 | 239 | -330 | -224 | 415 |
| Earnings Per Share, Basic | 3.01 | 5.09 | 3.71 | 0.98 | 5.38 | 6.56 | 8.13 | 7.45 | 9.22 | 4.28 | -5.52 | -3.58 | 6.55 |
| Earnings Per Share, Diluted | 2.67 | 4.79 | 3.51 | 0.93 | 5.23 | 6.41 | 7.96 | 7.3 | 9.09 | 4.22 | -5.52 | -3.58 | 6.1 |